Ashton, Nicholas J. http://orcid.org/0000-0002-3579-8804
Di Molfetta, Guglielmo http://orcid.org/0009-0001-5339-933X
Tan, Kübra
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Messing, Albee http://orcid.org/0000-0001-6049-0521
Article History
Received: 6 February 2024
Accepted: 23 March 2024
First Online: 1 April 2024
Declarations
:
: NJA, GDM, and KT report no conflicts of interest.KB has served as a consultant and is on advisory boards for Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).AM has served on scientific advisory boards or as a consultant for Ionis Pharmaceuticals and Alnylam Pharmaceuticals.